1 Biallelic loss of function variants in WBP4, encoding a spliceosome protein, result in a variable 2 neurodevelopmental delay syndrome 3 4 Eden Engal<sup>1,2\*</sup>, Kaisa Teele Oja<sup>3,4\*</sup>, Reza Maroofian<sup>5</sup>, Ophir Geminder<sup>1,2</sup>, Thuy-Linh Le<sup>6</sup>, Evyatar Mor<sup>7</sup>, 5 Naama Tzvi<sup>8</sup>, Naama Elefant<sup>8</sup>, Maha S. Zaki<sup>9</sup>, Joseph G. Gleeson<sup>10,11</sup>, Kai Muru<sup>3,4</sup>, Sander Pajusalu<sup>3,4</sup>, 6 Monica H. Wojcik<sup>12</sup>, Divya Pachat<sup>13</sup>, Marwa Abd Elmaksoud<sup>14</sup>, Won Chan Jeong<sup>15</sup>, Hane Lee<sup>15</sup>, Peter 7 Bauer<sup>16</sup>, Giovanni Zifarelli<sup>16</sup>, Henry Houlden<sup>5</sup>, Orly Elpeleg<sup>8,17</sup>, Chris Gordon<sup>6</sup>, Tamar Harel<sup>8,17</sup>, Katrin 8 Õunap<sup>3,4#</sup>, Maayan Salton<sup>1#</sup>, Hagar Mor-Shaked<sup>8,17#</sup> 9 10 11 <sup>1</sup> Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, 12 Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel 13 <sup>2</sup> Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of 14 Jerusalem, Jerusalem, Israel 15 <sup>3</sup> Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia 16 <sup>4</sup> Institute of Clinical Medicine, University of Tartu, Tartu, Estonia 17 <sup>5</sup> Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology, London, UK 18 <sup>6</sup> Institute Imagine, Paris, France 19 <sup>7</sup> Department of computer science, Ben-Gurion University of the Negev 20 <sup>8</sup> Department of Genetics, Hadassah Medical Organization, Jerusalem, Israel 21 <sup>9</sup> Department of Clinical Genetics, Human Genetics and Genome Research Institute, Cairo, Egypt 22 <sup>10</sup> Department of Neurosciences, University of California, San Diego, La Jolla, USA 23 <sup>11</sup> Rady Children's Institute for Genomic Medicine, San Diego, La Jolla, USA 24 <sup>12</sup> Broad Institute of MIT and Harvard, Cambridge, MA 25 26 <sup>13</sup>งคระจากไม่เครื่อนหลังสู่เลือน เลือน เลือน เลือน เลือน processes and should not be used to guide clinical practice.

<sup>14</sup> Neurology Unit, Alexandria University Children's Hospital, Department of Pediatrics, Faculty of 27 Medicine, Alexandria University, Alexandria, Egypt 28 <sup>15</sup> 3billion, Seoul, Korea 29 <sup>16</sup> CENTOGENE N.V., Am Strande 7, 18055 Rostock, Germany. 30 <sup>17</sup> Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel 31 32 \*,# These authors contributed equally. 33 34 35 36 37 **Corresponding authors:** 38 Hagar Mor-Shaked Ph.D. **Department of Genetics** 39 Hadassah-Hebrew University Medical Center 40 POB 12000 41 42 Jerusalem, Israel +(972)-2-6776931 (office) 43 44 +(972)-2-6777618 (fax) Email: hagarmor@hadassah.org.il 45 46 47 Keywords: pre-mRNA splicing, spliceosome, syndromic neurodevelopmental disorder, WBP4 48 49 50 ABSTRACT 51

Over two dozen spliceosome proteins are involved in human diseases, also referred to as spliceosomopathies. WBP4 (WW Domain Binding Protein 4) is part of the early spliceosomal complex, and was not described before in the context of human pathologies. Ascertained through GeneMatcher we identified eleven patients from eight families, with a severe neurodevelopmental syndrome with variable manifestations. Clinical manifestations included hypotonia, global developmental delay, severe intellectual disability, brain abnormalities, musculoskeletal and gastrointestinal abnormalities. Genetic analysis revealed overall five different homozygous loss-of-function variants in WBP4. Immunoblotting on fibroblasts from two affected individuals with different genetic variants demonstrated complete loss of protein, and RNA sequencing analysis uncovered shared abnormal splicing patterns, including enrichment for abnormalities of the nervous system and musculoskeletal system genes, suggesting that the overlapping differentially spliced genes are related to the common phenotypes of the probands. We conclude that biallelic variants in WBP4 cause a spliceosomopathy. Further functional studies are called for better understanding of the mechanism of pathogenicity.

INTRODUCTION 67 The spliceosome is a complex of RNA and proteins responsible for promoting accurate splicing. More 68 69 than two dozen spliceosome proteins are known to be involved in human diseases, also referred as spliceosomopathies. Despite the fundamental function of the spliceosome in all tissues, 70 spliceosomopathies are typically tissue specific, resulting in defects affecting only one cell type. For 71 72 example, the widely expressed SNRNP200 is part of the U4/U6 complex, and is a known cause of Retinitis pigmentosa 33, which affects exclusively the retina.<sup>2</sup> This observation suggests that the 73 particular components of the spliceosome play a crucial role in accurately splicing specific targets, 74 75 which can lead to the development of distinct pathologies. 76 WBP4 (WW Domain Binding Protein 4), previously known as FBP21, is a 376-amino acid spliceosome 77 protein that contains a zinc finger motif and two tandem-WW domains. It was first detected as part of the early spliceosomal complex, where it interacts with the U2-associated protein SF3B4, SIPP1, and 78 the core splicing protein SmB/B'. These interactions are facilitated by the transient multivalent 79 recognition of the WW domains with proline-rich sequences.3-6 Later it was found to be present 80 81 exclusively in the Spliceosome B complex (B complex-specific proteins) which acts directly before spliceosomal catalytic activation. WBP4 was found to bind and inhibit SNRNP200 similarly to C9ORF78 82 and TSSC4.<sup>7,8</sup> In the transition from the B to the Bact complex, the RNA helicase SNRNP200 unwinds 83 the U4/U6 duplex, releasing the U4 snRNP, and enabling the U6 snRNA to base-pair with the U2 snRNA, 84 forming a catalytically important stem-loop. 9,10 Thus, inhibition of SNRNP200 plays a crucial role in 85 splice site selection, which positions WBP4 as a key player with a vital role in determining the outcome 86 87 of splicing. Overall, WBP4 was shown to enhance splicing in vitro and in vivo,<sup>5</sup> and to regulate alternative 88 splicing, 11 but was not described before in the context of human pathologies. Here we report a severe 89 neurodevelopmental syndrome with variable manifestations caused by homozygous loss of function 90

91

(LOF) variants in the WBP4 gene in eight unrelated families.

MATERIAL AND METHODS 92 93 Ethics statement. The study was conducted in accordance with IRB-approved protocol 0306-10-HMO, 94 and in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of the University of Tartu (Certificate No 269/M-18 on 17.04.2017). Informed consent for participation 95 96 and for publication of facial photographs was obtained from the patient's parents. 97 Exome sequencing. Duo exome sequencing was performed for Family 1. Exonic sequences from DNA 98 were enriched with the SureSelect Human All Exon 50 Mb V5 Kit (Agilent Technologies, Santa Clara, 99 100 California, USA) (proband F1-II:1), or xGen Exome Research Panel v2 kit (Integrated DNA Technologies, 101 IDT) (proband F1-II:4). Sequences were generated on a NovaSeq6000 sequencing system (Illumina, San Diego, California, USA) as 150-bp paired-end runs. The FASTQs were uploaded into the Geneyx Analysis 102 platform.<sup>12</sup> Alignment and variant calling of single nucleotide variations (SNVs), structural variants 103 (SVs), CNVs and repeats were called using Illumina DRAGEN Bio-IT, with hg19 as human reference 104 105 genome. The resulting VCF files were comprehensively annotated on the Geneyx Analysis annotation engine, and presented for analysis, filtering and interpretation. Exome analysis of the probands yielded 106 107 40 and 120 million reads, with a mean coverage of 80 and 120X, in accordance. 108 For Family 2, trio exome sequencing was performed in clinical diagnostic settings at Tartu University Hospital. SureSelect Human All Exon V5 kit (Agilent Technologies, Santa Clara, California, USA) was 109 used for exome enrichment of the genomic DNA extracted from blood. The enriched exome was 110 sequenced on HiSeq 4000 (Illumina, San Diego, California, USA) platform. The data processing and 111 variant calling pipeline followed Genome Analysis Toolkit's best practice guidelines. 13 The specifics of 112 the in-house pipeline have been previously described. 14 Exome sequencing of families 3-6 were 113 sequenced and analyzed as published elsewhere. 15-17 114 115 Sanger sequencing. An amplicon containing the variant of interest was amplified by conventional PCR 116

117

of genomic DNA, and analyzed by Sanger dideoxy nucleotide sequencing.

Whole genome sequencing (Family 2). Whole genome sequencing and data processing were performed by the Genomics Platform at the Broad Institute of MIT and Harvard. PCR-free preparation of sample DNA (350 ng input at >2 ng/ul) is accomplished using Illumina HiSeq X Ten v2 chemistry. Libraries are sequenced to a mean target coverage of >30x. Genome sequencing data was processed through a pipeline based on Picard, using base quality score recalibration and local realignment at known indels. The BWA aligner was used for mapping reads to the human genome build 38. Single Nucleotide Variants (SNVs) and insertions/deletions (indels) are jointly called across all samples using Genome Analysis Toolkit (GATK) HaplotypeCaller package version 3.4. Default filters were applied to SNV and indel calls using the GATK Variant Quality Score Recalibration (VQSR) approach. Annotation was performed using Variant Effect Predictor (VEP). Lastly, the variant call set was uploaded to seqr for collaborative analysis between the CMG and investigator. Loss of heterozygosity regions was calculated by Manta, Smoove and Delly programs.

Diagnostic RNA sequencing. For Family 2, patient-derived fibroblasts were cultivated in AmnioMAX-c100. Human whole transcriptome sequencing was performed by the Genomics Platform at the Broad Institute of MIT and Harvard. The transcriptome product combines poly(A)-selection of mRNA transcripts with a strand-specific cDNA library preparation, with a mean insert size of 550bp. Libraries were sequenced on the HiSeq 2500 platform to a minimum depth of 50 million STAR-aligned reads. ERCC RNA controls are included for all samples, allowing additional control of variability between samples. STAR (version 2.5.3) aligner was used to map sequencing reads to GRCh38 reference genome; genes and transcripts were defined using GENCODE v26. To detect expression outliers STAR generated reads per gene counts of 40 unsolved pediatric patients with suspicion of a genetic disorder and 100 controls from GTEx were analyzed using R package OUTRIDER. Statistical significance was determined using a cut-off of 0.05 for the adjusted p-values. The results were analyzed collaboratively between Broad CMG and investigators from Tartu University Hospital.

Cell lines. CCD-1092Sk cells (ATCC Number: CRL-2114) and primary fibroblasts cells from biopsy were 143 grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum 144 145 (FBS). Cells were maintained at 37°C and 5% CO2 atmosphere. 146 Immunoblotting. For immunoblotting, cells were harvested and lysed with NP-40 1% lysis buffer, and 147 20 µg of the extracts were run on a 10% TGX Stain-free FastCast gel (BioRad) and transferred onto a 148 nitrocellulose membrane. Antibodies used for immunoblotting were anti-WBP4 (Bethyl Laboratories # 149 A305-693A-M), and anti-Actin. 150 151 152 RNA Sequencing and analysis. RNA from primary fibroblasts was isolated using the GENEzol™ TriRNA Pure Kit (Geneaid). RNA samples for three biological replicates (approximately 1×10<sup>6</sup> cells for family 1 153 and approximately 0.3×10<sup>6</sup> cells for family 2) were subjected to sequencing. Raw reads were assessed 154 using the FastQC tool v0.11.9. The processed reads were aligned to the human transcriptome and 155 genome version GRCh38 with annotations from using STAR v2.7.10.19 Counts per gene quantification 156 was done with featureCounts v2.0.1.<sup>20</sup> Normalization and differential expression analysis were done 157 with the DESeq2 package v 1.30.1.<sup>21</sup> Pair-wise comparisons were tested with default parameters (Wald 158 159 test), without applying the independent filtering algorithm. Significance threshold was taken as padj<0.05. In addition, significant DE genes were further filtered by the log2FoldChange value with 160 IfcThreshold=1. rMATS v4.1.2<sup>22</sup> was used to identify differential alternative splicing events. For each 161 162 alternative splicing event, we used the calculation on both the reads mapped to the splice junctions and the reads mapped to the exon body (JCEC). Significance threshold was taken as FDR<0.05. In 163 addition, significant splicing events were further filtered by the Inclusion level difference value for 164 165 InclDiff > |0.1|. Gene-set enrichment analysis was performed using the GeneAnalytics tool.<sup>23</sup> 166 167 Gene-phenotype relationship analysis. Gene-phenotype associations were calculated using Geneyx Analysis phenotyper tool. 168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

**RESULTS** Biallelic mutations in WBP4 cause highly variable neurodevelopmental syndrome To identify the genetic cause of a developmental delay and autism in a male child born to a consanguineous family (Figure 1A, F1-II:1), and of another affected offspring (individual F1-II:4; fetus with atrioventricular (AV)-canal, suspected absence of thymus, and intrauterine growth restriction), quad exome sequencing was performed. No pathogenic variants in genes known to be associated with neurological disorders were found, or any other known pathogenic events in both siblings. As the consanguineous background was suggestive for autosomal recessive inheritance, we focused on rare homozygous variants. A potentially harmful homozygous frameshift variant in WBP4 was found in both siblings (chr13:g. 41072793 GA > G; NM\_007187.5:c.499delA; p.(Thr167fs)(hg38)), predicted to result in a premature stop codon. Segregation study by Sanger sequencing revealed that the parents were heterozygous carriers, affected individuals were homozygous for the variant, and two unaffected siblings were either heterozygous or homozygous wild type (WT) (Figure 1A and Figure S1). This variant is absent from the Genome Aggregation Database (gnomAD), and no other homozygous LOF variant in this gene was described before. Through GeneMatcher<sup>24</sup>, a total of 11 affected individuals from eight families were identified, all carrying homozygous LOF variants (Table 1 and Figure 1A, 1C). All variants were absent or had an extremely low frequency (<0.01%) in public databases. Interestingly, some of the patients had a much more severe phenotype. The patient from Family 2 was a male patient born as a first child from a complicated pregnancy to non-consanguineous parents. Bilateral hydronephrosis, intrauterine growth retardation (IUGR) and mild oligohydramnios were seen during pregnancy in ultrasound. The child was born prematurely at 35+5 weeks of gestation via emergency C-section. At birth, all his growth parameters were below the 3rd percentile (weight 1616 g, length 40 cm, head circumference 29 cm). He had multiple congenital anomalies – anal atresia with fistula into bladder, distal hypospadia and cryptorchidism, bilateral hydronephrosis, congenital heart defect - atrial septal defect (VCC-ASD), agenesis of corpus callosum (CCA) and dysmorphic features

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

(dolichocephaly, proptosis, hypertelorism, depressed nasal bridge, microretrognathia). Clinically, the VACTERL association was diagnosed. He presented failure to thrive, bilateral neurosensory hearing loss, optic nerve atrophy, convergent strabismus, global developmental delay, hypotonia, dysphagia and frequent infections. Electroencephalogram showed altered electrical activity without epileptiform abnormalities, and brain Magnetic resonance imaging (MRI) confirmed the CCA and frontotemporal widening of subarachnoidal space (Figure 1B). Trio exome analysis was performed, but no pathogenic variants could be associated with the patient's phenotype. In early childhood, trio genome sequencing, RNA sequencing from fibroblast cell cultures and untargeted metabolomics analysis from serum were additionally performed. RNA sequencing revealed a very low expression of the WBP4 gene (Figure S3), and reanalysis of genome data indicated a homozygous deletion in this region (Figure S4). Homozygous deletion of the three last exons of the WBP4 gene was validated by Sanger sequencing. The deletion is located in a ~6.2 Mb size loss of heterozygosity (LOH)-region (precise coordinates for deletion chr13:41,074,140-41,090,168 (hg38)). The most common clinical features among the affected individuals in eight families were global developmental delay, muscular hypotonia, dysmorphic facial features and feeding difficulties or failure to thrive (Table 1). Morphological central nervous system abnormalities, atypical behavior and moderate to severe intellectual disability were present in almost half of the patients. In some cases congenital abnormalities of the heart, gastrointestinal, skeletal and/or urogenital system were evident. The individual clinical features are described in detail in supplementary materials (Table S1).

#### **RNA** sequencing analysis

Considering the fact that WBP4 codes for a spliceosome protein, we wished to understand how splicing is altered in cells lacking WBP4. For this, we took a skin biopsy from affected individuals F1-II:1 and F2-II:1 and their parents. Primary fibroblasts were grown and protein was extracted to evaluate the amount of WBP4 in the probands relative to their heterozygote parents and WT fibroblasts. Our results

show that in both cases the heterozygote parents show half of WBP4 protein amount relative to the 221 222 WT control and that probands with homozygous WBP4 mutations have total ablation of WBP4 protein 223 (Figure 2A). In addition, we extracted RNA from fibroblasts of the parents as well as probands and conducted RNA 224 sequencing (RNA-seq). WBP4 mRNA amount was reduced in proband F1-II:1, as is expected by an early 225 226 termination codon leading to nonsense mediated decay. In proband F2-II:1 expression was low and the transcript terminates at exon 7 out of 10 (NM\_007187.5) as expected by the deletion location 227 relative to the WBP4 gene (Figure S5). Following analysis of the RNA-seq results we detected 579 genes 228 229 with changes in gene expression in proband F1-II:1 relative to his parents (FDR<0.05, DEseq221). To 230 understand if these genes contribute to the proband's phenotype, we used the GeneAnalytics tool<sup>23</sup> 231 to identify diseases related to the gene set. The human phenotype ontology pointed at enrichment for skin related phenotypes. Analyzing the results of the F2-II:1 proband we found 1,068 genes with 232 altered gene expression as compared to his parents (FDR<0.05, DEseq221) with a human phenotype 233 234 enrichment of skin conditions as well as abnormalities in cardiovascular physiology (Figure S6A). We hypothesis that skin diseases enrichment which is not part of the probands' phenotypes could suggest 235 236 a difference in gene expression of skin-related genes between the young probands and their adult 237 parents' fibroblasts. Comparing the change in gene expression between the two probands we found 89 overlapping genes (P value<0.00001, Fisher exact test, Figure 2C) with no disease relevant gene set 238 enrichment (Figure S6B and Table S2). 239 We have used rMATS (version 4.1.2) to identify abnormal splicing in the probands.<sup>22</sup> Our analysis 240 241 identified 5,675 differential splicing events in 2,859 genes in proband F1-II:1 compared to his parents (Figure 2B, upper panel, Table S3). All types of splicing events were present: skipped exons (2,445 242 243 events), alternative 5' splice site (654 events), alternative 3' splice site (629 events), mutually exclusive exons (1,268 events) and intron retention (679 events). To check if the differentially spliced genes are 244 related to the proband's phenotype, we used the GeneAnalytics tool<sup>23</sup> and found enrichment for 245 abnormalities of the musculoskeletal and the nervous system (Figure 2C, upper panel). Comparing 246

proband F2-II:1 to his parents we identified 2,868 differential splicing events in 1,555 genes (Figure 2B, 247 lower panel, Table S3). Again, all types of splicing events were identified: skipped exons (1,361 events), 248 249 alternative 5' splice site (270 events), alternative 3' splice site (173 events), mutually exclusive exons (478 events) and intron retention (586 events). The human phenotype ontology pointed at genes 250 251 related to the nervous system and the musculoskeletal system similar to proband F1-II:1 (Figure 2C, 252 lower panel). While, WBP4 is expressed in all tissues it was found to be higher in the skeletal and heart muscles<sup>25</sup> (Figure S8). This higher expression corresponds to the abnormal splicing of the 253 musculoskeletal genes and to the heart anomaly - atrial septal defect in proband F2-II:1 (Table 1). 254 255 The principal components of the quantile normalized and standardized reads per exon show similarity 256 between the two probands and the distinction of each proband from his parents (Figure 3A). 257 Moreover, the probands samples are very distinct from samples of healthy, WBP4 +/+ children (Figure 3A). We continued to check the similarity in splicing events between the two probands and found 619 258 genes changing in splicing in both probands (Figure 3B, Figure S9A-C, and Table S3, P value<0.00001, 259 260 Fisher exact test). To check if the common differentially spliced genes in both probands are related to their phenotype, we used the GeneAnalytics tool to perform human phenotype enrichment analysis. 261 262 We found enrichment for abnormalities of the nervous system and musculoskeletal system, suggesting that the overlapping differentially spliced genes are related to the common phenotypes of the 263 probands (Figure 3C). Among the differentially spliced genes related to the probands' phenotype we 264 identified for example HUWE1, SMARCA2, SMARCC2, HNRNPH1 and TCF4. To understand if a 265 266 connection exists between regulation of expression to that of splicing by WBP4 we compared the genes changing in expression to that of splicing. We could find a small but significant overlap that can 267 be a result of an abnormal splicing event leading to a change in gene expression, as an inclusion of an 268 269 exon or a retained intron harboring a stop codon (Figure S9D-F). 270 Overall, the significant and shared alterations in splicing patterns in both patients, despite the district 271 ethnical change, point at a similar cause. As suggested by the role of WBP4 in the inhibition of 272 SNRNP200 and its exclusive presence in the B complex, where it acts directly before spliceosomal

catalytic activation, depletion of WBP4 in both patients leads to a similar pattern of abnormal splicing 273 and a shared pathomechanism of WBP4 loss of function. 274 In order to determine the clinical relevance of differentially expressed (DE) and aberrantly spliced (AS) 275 276 genes that the two probands (F1-II:1 and F2-II:1) had in common (89 and 619 genes respectively), we 277 performed gene-phenotype relationship analysis. We analyzed the association between DE and AS 278 genes symbols to 19 phenotypes found in at least 3 patients (Table 1). The search resulted in 46 (51.6%) and 356 (57.5%) directly related DE and AS genes (in accordance). 19.5% and 30% of the DE and AS 279 related genes had at least 10 out of 19 phenotypic matches (in accordance). In a combined analysis of 280 both DE and AS genes the top 10 highest ranking hits were all alternatively spliced - NFIX, TRIO, 281 282 ANKRD11, SZT2, HUWE1, PIGT, SMARCC2, PEX1, QRICH1, HRAS (Table S4). This indicates that the 283 alternatively spliced genes are more strongly connected to the patients' phenotype.

**DISCUSSION** 284 285 97% of human genes undergo pre-mRNA splicing, a process catalyzed by the spliceosome, a multi 286 subunit complex. The spliceosome is comprised of small noncoding RNA molecules (U1, U2, U4, U5 and U6) as well as proteins. <sup>26–29</sup> Among the spliceosome proteins, WBP4 is part of a group that plays a 287 critical role in splice site decisions. These B-complex-specific proteins act directly before spliceosomal 288 289 catalytic activation, fixing the specific splicing pattern of a substrate through irreversible loss of U4. In the transition from the B to the Bact complex, the RNA helicase SNRNP200 unwinds the U4/U6 duplex, 290 releasing the U4 snRNP and enabling the U6 snRNA to base-pair with the U2 snRNA and form a 291 292 catalytically important stem-loop. Therefore, WBP4 is a key player in spliceosomal activation. 293 Precise and fine-tuned gene expression is crucial for proper brain development. Neurodevelopment 294 regulatory pathways are coordinated in space and time to produce a well-connected neuronal network.<sup>30</sup> Over two dozen spliceosome proteins have been linked to human diseases, which are 295 collectively referred to as spliceosomopathies. The tissue-specific nature of most spliceosome 296 297 components suggests that they are not functionally equivalent. Studying spliceosomopathies can 298 increase our understanding of the spliceosome and its functions. 299 Here we report a highly variable neurodevelopment syndrome caused by homozygous loss of function 300 variants in WBP4, in eight different families. The clinical presentation of the different affected individuals was highly variable. Individuals F1-II:1 and 301 F2-II:1 presented the two sides of the spectrum, with one displaying a severe phenotype leading to 302 303 multiple malformations and premature death (F2-II:1) and one only showing much less severe 304 phenotype, with mainly intellectual disability and motor delay. Nevertheless, the two individuals have shared alterations in splicing patterns, stemming from WBP4 loss of function. While these phenotypic 305 306 differences might be due to the nature of the genetic variants (large deletion in F2-II:1 vs. a frameshift variant in F1-II:1), they could also be a characteristic of spliceosomopathies, as previously shown in 307 308 CWC27 mutations, which lead to a spectrum of conditions including retinal degeneration, short

stature, craniofacial abnormalities, brachydactyly, and neurological defects.<sup>31</sup> This is also supported by 309 the fact that both patients were shown to have complete loss of WBP4 protein. 310 Seven out of the top ten alternatively spliced genes with highest phenotype match, are known 311 autosomal dominant genes. This fits with the assumption that splicing alteration are incomplete, 312 mimicking a dominant effect. 313 One individual F2-II:1 presented the VACTERL association that comprises patients with at least three 314 of the following characteristic features - vertebral defects, anal atresia, cardiac defects, tracheo-315 esophageal fistula, renal anomalies, and limb abnormalities. It has previously shown that heterozygous 316 317 loss of WBP11 function cause a variety of overlapping congenital malformations, including cardiac, vertebral, tracheo-esophageal, renal and limb defects.<sup>32</sup> WBP11, similarly to WBP4, encodes a 318 319 component of the spliceosome with the ability to activate pre-messenger RNA splicing. WBP11 heterozygous null mice are small and exhibit defects in axial skeleton, kidneys and esophagus. Our 320 results support the conclusion of Martin et al 2020<sup>32</sup> that loss-of function WBP11 and WBP4 variants 321 322 should be considered as a possible cause of VACTERL association. Larger cohort of affected individuals is necessary to recapitulate the entire spectrum of the WBP4-323 324 related disorder, and further functional studies are called for better understanding of the mechanism of pathogenicity. 325 326 327 **ACKNOWLEDGEMENTS** 328 329 The authors wish to thank the families for their participation in this study. This work is supported by Estonian Research Council grants PRG471 and PSG774. The Broad Institute 330 Center for Mendelian Genomics (UM1HG008900) is funded by the National Human Genome Research 331 Institute with supplemental funding provided by the National Heart, Lung, and Blood Institute under 332 the Trans-Omics for Precision Medicine (TOPMed) program and the National Eye Institute. MHW is 333 supported by K23HD102589. 334

335 **AUTHOR CONTRIBUTIONS** 336 H.M.-S., K.T.O., M.S., and E.E. designed the study and wrote the paper. T.H. and K.O. supervised the 337 study, and contributed to writing the paper. H.M.-S. (F1) recognized this disease as a new clinical entity 338 with the F1. E.E. has performed the comparative RNA sequencing analyses, and O.G. grew fibroblasts, 339 extracted RNA and performed the western blot analyses, both under the supervision of M.S. N.E., M.T., 340 and O.E. (F1) provided genetic consultation and evaluation. K.M. and K.O. (F2) provided genetic 341 consultation and evaluation. S.P., M.H-W., K.O. and K.T.O. (F2) performed sequencing and analysis of 342 343 trio genome and RNA for F2. R.M (F3-6) coordinated the local clinical study. M.Z. (F4, F5) J.G. (F5) ... 344 D.P. (F6) provided genetic consultation and evaluation. C.G and T-L.L. (F7-8) performed sequencing and analyses and coordinated the local clinical study. 345 346 **DECLARATION OF INTERESTS** 347 HMS is an employee of Geneyx Genomics. Other authors declare no conflict of interest. 348 349 350 DATA AVAILABILITY The ClinVar accession number for the DNA variants data are: 351 SCV003922044 WBP4 NM 007187.5 c.499delA 352 SCV003922045 WBP4 NC\_000013.11 g.41074134\_41090164del 353 354 SCV003922046 WBP4 NM 007187.5 c.668C>G SCV003922047 WBP4 NM 007187.5 c.944delC 355 SCV003922048 WBP4 NM 007187.5 c.440-1G>A. 356 357 All analyzed data consists of patient's personal data and is stored according to regulations of the 358 institutions. Pseudonymized data is available on request. 359 360 **REFERENCES** 361 1. Griffin C, Saint-Jeannet JP. Spliceosomopathies: Diseases and mechanisms. Dev Dyn Off Publ Am 362 Assoc Anat. 2020;249(9):1038-1046. doi:10.1002/dvdy.214 363 2. Zhao C, Bellur DL, Lu S, et al. Autosomal-dominant retinitis pigmentosa caused by a mutation in 364 SNRNP200, a gene required for unwinding of U4/U6 snRNAs. Am J Hum Genet. 2009;85(5):617-365 627. doi:10.1016/j.ajhg.2009.09.020 366 3. Bedford MT, Reed R, Leder P. WW domain-mediated interactions reveal a spliceosome-367 associated protein that binds a third class of proline-rich motif: the proline glycine and 368 methionine-rich motif. Proc Natl Acad Sci U S A. 1998;95(18):10602-10607. 369 doi:10.1073/pnas.95.18.10602 370 4. Chan DC, Bedford MT, Leder P. Formin binding proteins bear WWP/WW domains that bind 371 proline-rich peptides and functionally resemble SH3 domains. EMBO J. 1996;15(5):1045-1054. 372 5. Huang X, Beullens M, Zhang J, et al. Structure and Function of the Two Tandem WW Domains of 373 374 the Pre-mRNA Splicing Factor FBP21 (Formin-binding Protein 21). J Biol Chem. 2009;284(37):25375-25387. doi:10.1074/jbc.M109.024828 375 376 6. Klippel S, Wieczorek M, Schümann M, et al. Multivalent Binding of Formin-binding Protein 21 (FBP21)-Tandem-WW Domains Fosters Protein Recognition in the Pre-spliceosome. J Biol Chem. 377 2011;286(44):38478-38487. doi:10.1074/jbc.M111.265710 378 379 7. Henning LM, Santos KF, Sticht J, et al. A new role for FBP21 as regulator of Brr2 helicase activity. Nucleic Acids Res. 2017;45(13):7922-7937. doi:10.1093/nar/gkx535 380 8. Bergfort A, Hilal T, Kuropka B, et al. The intrinsically disordered TSSC4 protein acts as a helicase 381 inhibitor, placeholder and multi-interaction coordinator during snRNP assembly and recycling. 382 Nucleic Acids Res. 2022;50(5):2938-2958. doi:10.1093/nar/gkac087 383 9. Raghunathan PL, Guthrie C. RNA unwinding in U4/U6 snRNPs requires ATP hydrolysis and the 384 385 DEIH-box splicing factor Brr2. Curr Biol CB. 1998;8(15):847-855. doi:10.1016/s0960-9822(07)00345-4 386 10. Laggerbauer B, Achsel T, Lührmann R. The human U5-200kD DEXH-box protein unwinds U4/U6 387 RNA duplices in vitro. Proc Natl Acad Sci U S A. 1998;95(8):4188-4192. 388 389 11. Woolard J, Vousden W, Moss SJ, et al. Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. Chem Sci R Soc Chem 2010. 2011;2011(2):273-278. 390 doi:10.1039/C0SC00297F 391 392 12. Dahary D, Golan Y, Mazor Y, et al. Genome analysis and knowledge-driven variant interpretation with TGex. BMC Med Genomics. 2019;12(1):200. doi:10.1186/s12920-019-0647-8 393 394 13. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinforma. 395 2013;43(1110):11.10.1-11.10.33. doi:10.1002/0471250953.bi1110s43 396 14. Pajusalu S, Reimand T, Õunap K. Novel homozygous mutation in KPTN gene causing a familial 397 intellectual disability-macrocephaly syndrome. Am J Med Genet A. 2015;167A(8):1913-1915. 398 399 doi:10.1002/ajmg.a.37105

400 15. Seo GH, Lee H, Lee J, et al. Diagnostic performance of automated, streamlined, daily updated exome analysis in patients with neurodevelopmental delay. Mol Med Camb Mass. 2022;28(1):38. 401 doi:10.1186/s10020-022-00464-x 402 403 16. Bertoli-Avella AM, Kandaswamy KK, Khan S, et al. Combining exome/genome sequencing with 404 data repository analysis reveals novel gene-disease associations for a wide range of genetic disorders. Genet Med Off J Am Coll Med Genet. 2021;23(8):1551-1568. doi:10.1038/s41436-021-405 406 01159-0 407 17. Makrythanasis P, Maroofian R, Stray-Pedersen A, et al. Biallelic variants in KIF14 cause intellectual disability with microcephaly. Eur J Hum Genet EJHG. 2018;26(3):330-339. 408 409 doi:10.1038/s41431-017-0088-9 410 18. Brechtmann F, Mertes C, Matusevičiūtė A, et al. OUTRIDER: A Statistical Method for Detecting 411 Aberrantly Expressed Genes in RNA Sequencing Data. Am J Hum Genet. 2018;103(6):907-917. 412 doi:10.1016/j.ajhg.2018.10.025 413 19. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 414 2013;14(4):R36. doi:10.1186/gb-2013-14-4-r36 415 20. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput 416 sequencing data. Bioinforma Oxf Engl. 2015;31(2):166-169. doi:10.1093/bioinformatics/btu638 417 418 21. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeg2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8 419 420 22. Shen S, Park JW, Lu Z xiang, et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A. 2014;111(51):E5593-5601. 421 doi:10.1073/pnas.1419161111 422 423 23. Ben-Ari Fuchs S, Lieder I, Stelzer G, et al. GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data. Omics J Integr Biol. 2016;20(3):139-424 151. doi:10.1089/omi.2015.0168 425 24. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting 426 427 investigators with an interest in the same gene. Hum Mutat. 2015;36(10):928-930. doi:10.1002/humu.22844 428 25. Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx) project. Nat 429 430 Genet. 2013;45(6):580-585. doi:10.1038/ng.2653 26. Grzybowska EA. Human intronless genes: functional groups, associated diseases, evolution, and 431 mRNA processing in absence of splicing. Biochem Biophys Res Commun. 2012;424(1):1-6. 432 doi:10.1016/j.bbrc.2012.06.092 433 434 27. Pena V, Rozov A, Fabrizio P, Lührmann R, Wahl MC. Structure and function of an RNase H domain at the heart of the spliceosome. EMBO J. 2008;27(21):2929-2940. doi:10.1038/emboj.2008.209 435 28. Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 2014;15(2):108-436 437 121. doi:10.1038/nrm3742

29. Lee Y, Rio DC. Mechanisms and Regulation of Alternative Pre-mRNA Splicing. *Annu Rev Biochem*. 438 2015;84:291-323. doi:10.1146/annurev-biochem-060614-034316 439 30. Tebbenkamp ATN, Willsey AJ, State MW, Šestan N. The Developmental Transcriptome of the 440 Human Brain: Implications for Neurodevelopmental Disorders. Curr Opin Neurol. 2014;27(2):149-441 156. doi:10.1097/WCO.0000000000000069 442 443 31. Xu M, Xie YA, Abouzeid H, et al. Mutations in the Spliceosome Component CWC27 Cause Retinal 444 Degeneration with or without Additional Developmental Anomalies. Am J Hum Genet. 2017;100(4):592-604. doi:10.1016/j.ajhg.2017.02.008 445 446 32. Martin EMMA, Enriquez A, Sparrow DB, et al. Heterozygous loss of WBP11 function causes 447 multiple congenital defects in humans and mice. Hum Mol Genet. 2020;29(22):3662-3678. doi:10.1093/hmg/ddaa258 448 449


FIGURE LEGENDS 450 Figure 1. Clinical and genetic findings in eight families with WBP4-related syndrome. A. Pedigrees of 451 eight families with WBP4-related syndrome. Symbols: filled black - affected individuals; diagonal line 452 - deceased; double line - consanguinity; arrows indicate the probands. In each family the likely 453 pathogenic variant in WBP4 is written beneath the pedigree using NM 007187.5 transcript. 454 Homozygotes for the likely pathogenic variant are noted as -/- and heterozygotes as +/-. F2:II-1 died of 455 aspiration pneumonia in childhood. F5-II:4 died of intestinal obstruction in infancy; the parents of the 456 457 proband (I:1 and I:2) are from the same village. F8-II:1 died in infancy due to cardiopathy. B. Magnetic resonance images (MRI) of two patients during their early childhood. MRI of F2-II:1 shows agenesis of 458 459 corpus callosum (arrow) and a midsagittal T1-weighted MRI of F4-II:1 shows hypoplastic corpus callosum (arrow). C. Schematic diagram of WBP4 transcript NM\_007187.5 and the five LOF variants 460 461 identified in our study. The gray rectangles represent exons 1-10 starting from left to right. The functional domains (zinc finger, WW1, WW2) of the protein are drawn below as blue and green 462 463 rectangles. 464 Figure 2. Immunoblotting and RNA sequencing analysis in Families 1 and 2. A. Western blot was 465 466 performed to analyze the expression levels of WBP4 and actin proteins in fibroblast cell cultures from controls, family 1 (F1-I:2 mother, F1-I:1 father, F1-II:1 proband) and family 2 (F2-I:2 mother, F2-I:1 467 father, F2-II:1 proband). B. Summary of significant abnormal splicing events (FDR<0.05, IncLDiff < 468 [0.1] identified using rMATS in individual F1-II:1 (upper panel) and individual F2-II:1 (lower panel). C. 469 Gene set enrichment for human phenotypes in individual F1-II:1 (upper panel) and individual F2-II:1 470 (lower panel). Enrichment is represented as the number of genes matching each human phenotype 471 472 and the enrichment significance (-(Log10) P-value). 473 Figure 3. Common abnormal splicing events in F1-II:1 -/- and F2-II:1 -/-. A. RNA was extracted from 474


fibroblasts of F1-I:2 +/-, F1-I:1 +/-, F1-II:1 -/-, F2-I:2 +/-, F2-I:1 +/- and F2-II:1 -/- fibroblasts and


475

subjected to sequencing. Principal component analysis plot of PC1 and PC2 representing the variance 476 between normalized exon read-counts in the two probands and their WBP4 +/- relatives. B. Venn 477 diagram representing the overlap in splicing between the two affected individuals (F1-II:1 and F2-II:1). 478 C. Gene set enrichment analysis for 619 overlapping abnormally spliced genes. Gene set enrichment 479 for human phenotypes, enrichment is represented as the number of genes matching each human 480 phenotype and the enrichment significance (-(Log10) P-value).


# Figure 1







## Figure 2








Figure 3





## В

### Alternatively spliced genes



C




Table 1. Summary of the demographic, genetic and clinical features of individuals with WBP4-related syndrome. All patients are homozygous for the variant in WBP4 and the frequency of characteristics is presented as a ratio of patients with the feature to patients with data.

Characteristic	Individuals with WBP4- related syndrome (n=11)
Age at last investigation, years (n=8)	
Median	3
Range	1.25 to 10
Gender	
Female	8/11
Ethnicity	
Egyptian	5/9
Arab Muslim	2/9
Estonian	1/9
Indian	1/9
WBP4 variant (%)	
c.499delA	7/11
c.562+1278_*7251del	1/11
c.668C>G	1/11
c.944delC	1/11
c.440-1G>A	1/11
Motor delay	8/8
Speech delay	8/8
Hypotonia	7/7
Dysmorphic facial features	·
Abnormality of the outer ear	6/7
Abnormal palate morphology	4/8
Hypertelorism	4/6
Fine hair	3/7
Feeding difficulties / Failure to thrive	6/7
Aplasia/Hypoplasia of the corpus callosum	5/8
Other morphological central nervous system	5/8
abnormalities	
Atypical behavior	
Autistic features	5/7
Hyperactivity	5/7
Stereotypy	4/7
Sleep-wake cycle disturbance	4/5
Intellectual disability	5/5
Congenital heart defect	4/7
Prenatal issues	3/10
Urogenital abnormalities	3/10
Weight and height <-2 SD at last investigation	3/6
Skeletal abnormalities	3/4